5-lipoxygenase is a candidate target for therapeutic management of stem cell-like cells in acute myeloid leukemia

Cancer Research

Volumn 74, Issue 18, 2014, Pages 5244-5255

  Roos, Jessica ^a   Oancea, Claudia ^a   Heinssmann, Maria ^a   Khan, Dilawar ^a   Held, Hannelore ^a   Kahnt, Astrid S ^a   Capelo, Ricardo ^a   La Buscató, Estel ^a   Proschak, Ewgenij ^a   Puccetti, Elena ^b   Steinhilber, Dieter ^a   Fleming, Ingrid ^a   Maier, Thorsten J ^a,c   Ruthardt, Martin ^a  

^a GOETHE UNIVERSITY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; LIPOXYGENASE INHIBITOR;

ANIMAL; C57BL MOUSE; CANCER STEM CELL; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENETIC TRANSFECTION; HEK293 CELL LINE; HUMAN; LEUKEMIA, MYELOID, ACUTE; MALE; METABOLISM; MOUSE; PATHOLOGY; PLASMID; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; CELL LINE, TUMOR; FEMALE; HEK293 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIPOXYGENASE INHIBITORS; MALE; MICE; MICE, INBRED C57BL; NEOPLASTIC STEM CELLS; PLASMIDS; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84907487904     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3012     Document Type: Article

References (53)

1. Alison MR, Lin WR, Lim SM, Nicholson LJ. Cancer stem cells: in the line of fire. Cancer Treat Rev 2012;38:589-98.
2. Debeb BG, Lacerda L, Xu W, Larson R, Solley T, Atkinson R, et al. Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/beta-catenin signaling. Stem Cells 2012;30:2366-77.
3. Roarty K, Rosen JM. Wnt and mammary stem cells: hormones cannot fly wingless. Curr Opin Pharmacol 2010;10:643-9.
4. Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH, Borovski T, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010;12:468-76.
5. Heidel FH, Bullinger L, Feng Z, Wang Z, Neff TA, Stein L, et al. Genetic and pharmacologic inhibition of beta-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell 2012;10:412-24.
6. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010;327:1650-3.
7. Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007;12:528-41.
8. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657-67.
9. Passegue E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci U S A 2003;100:11842-9.
10. Muller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S, et al. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 2004;24:2890-904.
11. Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 2003;3:89-101.
12. Zheng X, Beissert T, Kukoc-Zivojnov N, Puccetti E, Altschmied J, Strolz C, et al. Gamma-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells. Blood 2004;103:3535-43.
13. Boon EM, Keller JJ, Wormhoudt TA, Giardiello FM, Offerhaus GJ, van der Neut R, et al. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer 2004;90:224-9.
14. Dihlmann S, Klein S, Doeberitz Mv MK. Reduction of beta-catenin/T-cell transcription factor signaling by aspirin and indomethacin is caused by an increased stabilization of phosphorylated beta-catenin. Mol Cancer Ther 2003;2:509-16.
15. Gardner SH, Hawcroft G, Hull MA. Effect of nonsteroidal anti-inflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells. Br J Cancer 2004;91:153-63.
16. Steinert G, Oancea C, Roos J, Hagemeyer H, Maier T, Ruthardt M, et al. Sulindac sulfide reverses aberrant self-renewal of progenitor cells induced by the AML-associated fusion proteins PML/RARalpha and PLZF/RARalpha. PLoS ONE 2011;6:e22540.
17. Steinbrink SD, Pergola C, Buhring U, George S, Metzner J, Fischer AS, et al. Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations. Cell Mol Life Sci 2010;67:797-806.
18. Chen Y, Hu Y, Zhang H, Peng C, Li S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet 2009;41:783-92.
19. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/-colon carcinoma. Science 1997;275:1784-7.
20. Oancea C, Ruster B, Henschler R, Puccetti E, Ruthardt M. The t (6;9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation. Leukemia 2010;24:1910-9.
21. Fischer AS, Metzner J, Steinbrink SD, Ulrich S, Angioni C, Geisslinger G, et al. 5-Lipoxygenase inhibitors induce potent anti-proliferative and cytotoxic effects in human tumour cells independently of suppression of 5-lipoxygenase activity. Br J Pharmacol 2010;161:936-49.
22. Werz O, Steinhilber D. Selenium-dependent peroxidases suppress 5-lipoxygenase activity in B-lymphocytes and immature myeloid cells. The presence of peroxidase-insensitive 5-lipoxygenase activity in differentiated myeloid cells. Eur J Biochem/FEBS 1996;242:90-7.
23. Maier TJ, Tausch L, Hoernig M, Coste O, Schmidt R, Angioni C, et al. Celecoxib inhibits 5-lipoxygenase. Biochem Pharmacol 2008;76:862-72.
24. Bug G, Gul H, Schwarz K, Pfeifer H, Kampfmann M, Zheng X, et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res 2005;65:2537-41.
25. Ruthardt M, Testa U, Nervi C, Ferrucci PF, Grignani F, Puccetti E, et al. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling. Mol Cell Biol 1997;17:4859-69.
26. Dannhardt G, Kiefer W. Cyclooxygenase inhibitors-current status and future prospects. Eur J Med Chem 2001;36:109-26.
27. Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, Maziasz TJ, et al. Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity. J Pharmacol Exp Ther 2005;312:1206-12.
28. Greenspan EJ, Madigan JP, Boardman LA, Rosenberg DW. Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}. Cancer Prev Res 2011;4:161-71.
29. Maier TJ, Janssen A, Schmidt R, Geisslinger G, Grosch S. Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J 2005;19:1353-5.
30. Riddick CA, Ring WL, Baker JR, Hodulik CR, Bigby TD. Dexamethasone increases expression of 5-lipoxygenase and its activating protein in human monocytes and THP-1 cells. Eur J Biochem 1997;246:112-8.
31. Wojiski S, Guibal FC, Kindler T, Lee BH, Jesneck JL, Fabian A, et al. PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors. Leukemia 2009;23:1462-71.
32. Fromel T, Jungblut B, Hu J, Trouvain C, Barbosa-Sicard E, Popp R, et al. Soluble epoxide hydrolase regulates hematopoietic progenitor cell function via generation of fatty acid diols. Proc Natl Acad Sci U S A 2012;109:9995-10000.
33. Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock BD. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 2007;50:3825-40.
34. Coulombel L. Identification of hematopoietic stem/progenitor cells: strength and drawbacks of functional assays. Oncogene 2004;23:7210-22.
35. Chen XS, Sheller JR, Johnson EN, Funk CD. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 1994;372:179-82.
36. Uhl J, Klan N, Rose M, Entian KD, Werz O, Steinhilber D. The 5-lipoxygenase promoter is regulated by DNA methylation. J Biol Chem 2002;277:4374-9.
37. Kargman S, Rousseau P, Reid GK, Rouzer CA, Mancini JA, Rands E, et al. Leukotriene synthesis in U937 cells expressing recombinant 5-lipoxygenase. J Lipid Mediat 1993;7:31-45.
38. Radmark O, Werz O, Steinhilber D, Samuelsson B. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci 2007;32:332-41.
39. Barker N, Clevers H. Catenins, Wnt signaling and cancer. Bioessays 2000;22:961-5.
40. Puccetti E, Obradovic D, Beissert T, Bianchini A, Washburn B, Chiaradonna F, et al. AML-associated translocation products block vitamin D (3)-induced differentiation by sequestering the vitamin D (3) receptor. Cancer Res 2002;62:7050-8.
41. Ruthardt M, Orleth A, Tomassoni L, Puccetti E, Riganelli D, Alcalay M, et al. The acute promyelocytic leukaemia specific PML and PLZF proteins localize to adjacent and functionally distinct nuclear bodies. Oncogene 1998;16:1945-53.
42. Cook BD, Ferrari G, Pintucci G, Mignatti P. TGF-beta1 induces rearrangement of FLK-1-VE-cadherin-beta-catenin complex at the adherens junction through VEGF-mediated signaling. J Cell Biochem 2008;105:1367-73.
43. Kajiguchi T, Chung EJ, Lee S, Stine A, Kiyoi H, Naoe T, et al. FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells. Leukemia 2007;21:2476-84.
44. Li Y, Gao Q, Yin G, Ding X, Hao J. WNT/beta-catenin-signaling pathway stimulates the proliferation of cultured adult human sertoli cells via upregulation of C-myc expression. Reprod Sci 2012;19:1232-40.
45. Carter GW, Young PR, Albert DH, Bouska J, Dyer R, Bell RL, et al. 5-lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther 1991;256:929-37.
46. Fischer L, Steinhilber D, Werz O. Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13, 610. Br J Pharmacol 2004;142:861-8.
47. McGill KA, Busse WW. Zileuton. Lancet 1996;348:519-24.
48. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005;310:1504-10.
49. Wang B, Yu SC, Jiang JY, Porter GW, Zhao LT, Wang Z, et al. An inhibitor of arachidonate 5-lipoxygenase, Nordy, induces differentiation and inhibits self-renewal of glioma stem-like cells. Stem Cell Rev 2011;7:458-70.
50. DeKelver RC, Lewin B, Lam K, Komeno Y, Yan M, Rundle C, et al. Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of Alox5 in acute myeloid leukemia. PLoS Genet 2013;9:e1003765.
51. Oancea C, Rüster B, Brill B, Roos J, Heinssmann M, Bug G, et al. STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t (6;9)-positive AML. 2014. Submitted for publication.
52. Catalano A, Caprari P, Soddu S, Procopio A, Romano M. 5-lipoxygenase antagonizes genotoxic stress-induced apoptosis by altering p53 nuclear trafficking. FASEB J 2004;18:1740-2.
53. Flamand N, Lefebvre J, Surette ME, Picard S, Borgeat P. Arachidonic acid regulates the translocation of 5-lipoxygenase to the nuclear membranes in human neutrophils. J Biol Chem 2006;281:129-36.